It had been shown previously that exogenous administration of FGF21 significantly lowers circulating and intrahepatic triglycerides, reverses fatty liver, and reduces signs of NASH and hepatic fibrosis (23). The gene discussed is FGF21; the disease is Hepatic steatosis.